Cibc World Markets Corp Cuts Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Cibc World Markets Corp decreased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 22.1% during the 4th quarter, Holdings Channel reports. The institutional investor owned 1,913 shares of the biotechnology company’s stock after selling 543 shares during the period. Cibc World Markets Corp’s holdings in United Therapeutics were worth $675,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the stock. Wealthfront Advisers LLC boosted its position in shares of United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock valued at $6,462,018,000 after buying an additional 18,313,424 shares during the last quarter. Geode Capital Management LLC lifted its holdings in United Therapeutics by 4.3% during the third quarter. Geode Capital Management LLC now owns 1,094,015 shares of the biotechnology company’s stock worth $391,459,000 after acquiring an additional 45,566 shares during the period. FMR LLC lifted its holdings in United Therapeutics by 41.1% during the third quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after acquiring an additional 314,004 shares during the period. Pacer Advisors Inc. lifted its holdings in United Therapeutics by 5.5% during the fourth quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock worth $210,869,000 after acquiring an additional 30,931 shares during the period. Finally, Janus Henderson Group PLC lifted its holdings in United Therapeutics by 12.3% during the third quarter. Janus Henderson Group PLC now owns 460,419 shares of the biotechnology company’s stock worth $164,978,000 after acquiring an additional 50,409 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Activity

In related news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $361.95, for a total transaction of $3,619,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at $932,745.15. The trade was a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the transaction, the director now owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 90,255 shares of company stock worth $32,614,521. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $312.99 on Friday. The stock has a market cap of $14.06 billion, a PE ratio of 13.75, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64. United Therapeutics Co. has a fifty-two week low of $221.53 and a fifty-two week high of $417.82. The stock has a fifty day moving average of $345.10 and a 200-day moving average of $357.02.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the business earned $4.36 earnings per share. On average, sell-side analysts predict that United Therapeutics Co. will post 24.48 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on UTHR. UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. HC Wainwright reiterated a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. Finally, StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.